- Conditions
- Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 176
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OPT-302, ranibizumab, sham intravitreal injection
- Biological · Other
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 49 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Southern California Desert Retina Consultants, MC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Placebo, LFG316
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
- Conditions
- Recalcitrant Wet Age-related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- NeoVista Ophthalmic System
- Device
- Lead sponsor
- NeoVista
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • San Antonio, Texas
- Conditions
- Macular Degeneration
- Interventions
- pazopanib eye drops, placebo, ranibizumab intravitreal injection
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- RBM-007
- Drug
- Lead sponsor
- Ribomic USA Inc
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 3 more
- Conditions
- Exudative Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 65
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Drug
- Lead sponsor
- Alcon, a Novartis Company
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Age-Related Macular Degeneration (AMD)
- Interventions
- PAN-90806 Ophthalmic Solution, Lucentis
- Drug
- Lead sponsor
- PanOptica, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 22
- States / cities
- Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
- Conditions
- Macular Degeneration
- Interventions
- MSI-1256F (Squalamine Lactate)
- Drug
- Lead sponsor
- Genaera Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Plymouth Meeting, Pennsylvania
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 331,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Wet Macular Degeneration
- Interventions
- Aflibercept Ophthalmic, optovue angiovue
- Drug · Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 60
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 627 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Diego, California + 10 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 14
- States / cities
- Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
- Drug
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Macular Degeneration, Maculopathy, Age-Related
- Interventions
- anecortave acetate
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas